Clinical Trials Logo

Lorazepam clinical trials

View clinical trials related to Lorazepam.

Filter by:
  • None
  • Page 1

NCT ID: NCT04671836 Withdrawn - Neuroimaging Clinical Trials

Lorazepam Effects on Neuroimaging Measures

Start date: January 2022
Phase: Early Phase 1
Study type: Interventional

This within-subject, double blind, randomized controlled study will investigate the effects of a widely used benzodiazepine (BZD), lorazepam, on various neuroimaging measures. The investigators will be assessing the relationship of lorazepam to resting state functional connectivity and other neuroimaging measures. Specifically, the investigators will be using a pre-identified metric, the striatal connectivity index (SCI), (Sarpal et al. 2015, 2016), a prognostic biomarker of treatment response assessing the connectivity between regions of the striatum and the cortex. The investigators hypothesize that lorazepam administration will be associated with greater SCI values compared with placebo administration; consistent with previous work suggesting short-acting benzodiazepines increase functional connectivity across brain networks.